Provided are a highly-sensitive antibody and a test reagent using the antibody.

A method for detecting an analyte according to an immunoassay method, using a carrier on which an antigen, an antibody or an antigen-binding fragment thereof is immobilized, wherein the analyte is detected with increasing detection sensitivity by using a carrier to which an antigen, an antibody or an antigen-binding fragment thereof was immobilized by adding disaccharide and sugar alcohol to a solution comprising an antigen, an antibody or an antigen-binding fragment thereof.

Methods for the treatment of a respiratory infection, for the prevention of worsening of symptoms associated with the infection, and for reducing the lethality of the infection such as but not limited to respiratory infections caused by a coronavirus. The present disclosure provides specific gaseous nitric oxide (NO) dosing regimens optionally paired with the monitoring of toxicology outcomes so as to enable the use of effective NO doses for treatment purposes. The present invention also discloses air circulation systems featuring NO for helping to prevent respiratory infections.

The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.

A fusion protein is provided which is based on a self-assembling gene-regulatory NSP10 protein and a protein or peptide capable of being fused to NSP10 without interfering with the assembly or aggregation of the resulting fusion protein. The disclosure also relates to any nanoparticle formed thereby whether complete or not, and methods for the use of the NSP10 fusion protein are also disclosed, including use as vaccines for any indication in humans or animals, therapeutic methods involving the use of the fusion proteins such as using the protein to targeted an antibody or receptor, such as for treating or diagnosing cancer, biosensors using the fusion protein, or the use of the fusion proteins in cell sorting or any imaging application.

A method for collection and dissemination of biologic data, comprising collecting at least one biologic sample by a testing device including thereon an alignment target and including a plurality of immunoassay test strips, wherein the at least one biologic sample contacts a sample pad on at least one of the plurality of immunoassay test strips, assigning correlative values as test results, wherein each test performed on the biologic sample is assigned a different correlative value, receiving the test results at a server disposed on a network, wherein the server has configured thereon a database, assigning a unique identification to the biologic sample, storing the unique identification in the database, storing the test results in the database in association with the unique identification of the biologic sample, and providing access to the database to healthcare organizations for analysis of the test results.

The present invention relates to hemagglutinin-specific antibodies, fragments thereof, and uses thereof. More specifically, these antibodies and fragments thereof are able to recognize antigen from multiple influenza strains.

The present invention is directed to methods and compositions for norovirus therapeutics, such as vaccines, and diagnostics.

Biosensors are provided for the detection of pathogens such as viruses. The sensors can includes a substrate, and a film disposed on the substrate. The film can include an electrically-conducting polymer, and an aromatic dialdehyde such as terephthaldehyde. The sensors experience a fast and repeatable decrease in electrical conductivity in the presence of certain pathogens, including the SARS-Cov-2 pseudo virus.

The presence of analytes can be detected in the bodily fluid using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (ECS) in devices, such as handheld point-of-care devices. The devices, as well as systems and methods, utilize using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (EIS) in combination with an antibody or other target-capturing molecule on a working electrode. Imaginary impedance or phase shift, as well as background subtraction, also may be utilized.

Machine learning analysis for classifying agglutination of fluid samples. A method includes scanning a unique scannable code printed on a test card, wherein the test card comprises a negative control fluid sample, a positive control fluid sample, and a test fluid sample. The method includes capturing an image of the test card and providing the image of the test card to a machine learning algorithm configured to assess agglutination of the test fluid sample based on the image. The method includes receiving from the machine learning algorithm one or more of a qualitative analysis or a quantitative analysis of the agglutination of the test fluid sample.